No clinical pregnancy is achieved after at least 12 months of regular unprotected sexual intercourse.
Conditions
Interventions
Control group:Endometrial transformation and embryo transfer were performed in this cycle.
GnRH-a+HMG group:Oral dydrogesterone tablets 10 mg three times daily were initiated on the same day, administered once daily for a total of 7 days. Seven days later, a GnRH-a injection of 0.5–0.7 mg w
once they reached baseline levels (LH <= 10 IU/L, P <= 4.7 nmol/L, E2 <= 180 pmol/L), daily injections of HMG at a dose of 150–225 IU were started. After 4–5 days, serum LH, P, and E2 levels were reas
Sponsors
The First Affiliated Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
Female
Age
20 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1. Patients who have experienced thin endometrium (TE) during assisted reproductive treatment at this center. Thin endometrium is defined as endometrial thickness =21 days). 3. Age =7 cells. Blastocysts with a quality >=3BC are considered viable. 5. Participants voluntarily agree to join this clinical trial, understand the study, and can provide signed informed consent.
Exclusion criteria
Exclusion criteria: 1.Untreated unilateral or bilateral hydrosalpinx detected on ultrasound, with a transverse diameter >20 mm, or a transverse diameter 4 cm or submucosal fibroids. 6.Patients with unexplained recurrent implantation failure (RIF) or recurrent pregnancy loss. RIF is defined in this study as the failure to achieve clinical pregnancy after the transfer of at least four high-quality cleavage-stage embryos or two viable blastocysts within two fresh or frozen cycles. Recurrent pregnancy loss is defined as two or more consecutive pregnancy losses before 28 weeks of gestation with the same partner; 7.History of severe ovarian hyperstimulation syndrome (OHSS) after ovarian stimulation. OHSS grading follows the classification criteria by Golan(1989). 8.History of poor ovarian response during ovarian stimulation, with <3 oocytes retrieved. 9.Other conditions deemed by the investigator as unsuitable for participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical pregnancy rate per transfer; | — |
Secondary
| Measure | Time frame |
|---|---|
| Endometrial thickness on the day of endometrial transformation and embryo transfer;Ongoing pregnancy rate per transfer;Cycle Cancellation Rate;Ectopic Pregnancy Rate;Early spontaneous miscarriage rate;Uterine spiral artery PI, RI, S/D and endometrial VI, FI, VFI;Uterine spiral artery PI, RI, S/D and endometrial VI, FI, VFI;OHSS Incidence Rate;Estradiol level on the day of endometrial transformation;Embryo implantation rate; | — |
Countries
China
Contacts
Public ContactHuang Xuefeng
The First Affiliated Hospital of Wenzhou Medical University
Outcome results
None listed